Clinical Trials
16 trialsNCT00544115 2025-06-10
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
Phase 2 Active not recruiting
NCT02220985 2025-06-04
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00534430 2025-06-03
Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT00540995 2023-11-30
Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer
City of Hope Medical Center
Phase 1/2 Terminated
NCT00816413 2023-08-14
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
University of Nebraska
Phase 1/2 Withdrawn
NCT02960646 2023-02-16
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00068523 2020-07-27
Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
Phase NA Completed
NCT00281879 2017-09-27
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00104975 2016-12-15
Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Yale University
Phase 1 Completed
NCT00003619 2013-06-26
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00521430 2013-03-26
Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease
National Cancer Institute (NCI)
Phase NA Completed
NCT00301912 2012-10-02
Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
University of California, San Francisco
Phase 2 Withdrawn
NCT00002833 2012-07-30
Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00732316 2012-07-17
Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematologic Cancer or Myelodysplastic Syndrome
Asan Medical Center
Phase 2 Completed
NCT00006379 2011-12-08
Non-Ablative Allo HSCT For Hematologic Malignancies or SAA
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00027924 2010-04-02
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
Phase 2 Completed